Trials that use: Risk difference
New to this method? Read the tutorial →
6,276 results
- Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307): Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02964559).
- Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02267603).
- Pembrolizumab in Treating Patients With Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02337686).
- Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy:…
- Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05): Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma: primary endpoint results, effect estimate with confidence interval,…
- Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Pemetrexed Plus Gemcitabine in Renal Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed Plus Gemcitabine in Renal Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00491075).
- Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pen PreferenceIndependent statistical analysis of Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus: primary endpoint results,…
- Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Penicillin De-labeling in the Pediatric Primary Care Setting: Complete Statistical AnalysisIndependent statistical analysis of Penicillin De-labeling in the Pediatric Primary Care Setting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05010304).
- Penn State TXT2Quit Study: Complete Statistical AnalysisIndependent statistical analysis of Penn State TXT2Quit Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02367391).
- Penn State TXT2STAYQUIT Study- a Texting Study to Help Hospitalized Smokers Stay Quit: Complete Statistical AnalysisIndependent statistical analysis of Penn State TXT2STAYQUIT Study- a Texting Study to Help Hospitalized Smokers Stay Quit: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pento & tBUIndependent statistical analysis of Phase II Trial of Pentostatin and Targeted Busulfan: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00496340).
- Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- PEPIIndependent statistical analysis of Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00578864).
- Peptide Vaccination for Patients at High Risk for Recurrent Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Peptide Vaccination for Patients at High Risk for Recurrent Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00059475).
- Perampanel in Seizure Patients With Primary Glial Brain Tumors: Complete Statistical AnalysisIndependent statistical analysis of Perampanel in Seizure Patients With Primary Glial Brain Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02363933).
- PERFECTIONIndependent statistical analysis of Evaluation of FUSION™ Vascular Graft for Above Knee Targets: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01601496).
- PERFORMIndependent statistical analysis of Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma: primary endpoint results, effect estimate with confidence interval,…
- Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms: Complete Statistical AnalysisIndependent statistical analysis of Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Performance Comparison Between Masimo W1™ and Apple Watch Series 8: Complete Statistical AnalysisIndependent statistical analysis of Performance Comparison Between Masimo W1™ and Apple Watch Series 8: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05968079).
- Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics: Complete Statistical AnalysisIndependent statistical analysis of Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Performance Evaluation of the AMIA APD Solution Generation System in Patients End Stage Renal Disease (ESRD): Complete Statistical AnalysisIndependent statistical analysis of Performance Evaluation of the AMIA APD Solution Generation System in Patients End Stage Renal Disease (ESRD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Performance of an Investigational Blood Glucose Monitoring System in a Clinical Trial: Complete Statistical AnalysisIndependent statistical analysis of Performance of an Investigational Blood Glucose Monitoring System in a Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Performance of Masimo INVSENSOR00057 in Detecting Atrial Fibrillation (Afib): Complete Statistical AnalysisIndependent statistical analysis of Performance of Masimo INVSENSOR00057 in Detecting Atrial Fibrillation (Afib): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05472012).
- Performance of Toric Hydrogel Lenses Following A Refit With Toric Silicone Hydrogel Lenses for 1 Month: Complete Statistical AnalysisIndependent statistical analysis of Performance of Toric Hydrogel Lenses Following A Refit With Toric Silicone Hydrogel Lenses for 1 Month: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Performance of Two Toric Silicone Hydrogel Contact Lenses: Complete Statistical AnalysisIndependent statistical analysis of Performance of Two Toric Silicone Hydrogel Contact Lenses: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03578926).
- Pericoital Oral Contraception With Levonorgestrel: Complete Statistical AnalysisIndependent statistical analysis of Pericoital Oral Contraception With Levonorgestrel: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00922233).
- Perioperative Blood Pressures and Chronic Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Perioperative Blood Pressures and Chronic Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02136810).
- Peripheral Nerve Blocks for Above-the-knee Amputations: Complete Statistical AnalysisIndependent statistical analysis of Peripheral Nerve Blocks for Above-the-knee Amputations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03404180).
- Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass: Complete Statistical AnalysisIndependent statistical analysis of Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PERSISTIndependent statistical analysis of Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01358357).
- Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines: Complete Statistical AnalysisIndependent statistical analysis of Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines: primary endpoint results, effect estimate with confidence interval, sample-size…
- Persistence of Protection by Shingrix: Complete Statistical AnalysisIndependent statistical analysis of Persistence of Protection by Shingrix: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04169009).
- Persistent Postoperative Pain and Joint Stiffness After Total Knee Arthroplasty Performed for Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Persistent Postoperative Pain and Joint Stiffness After Total Knee Arthroplasty Performed for Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Personalized Vitamin D Supplementation in European and African Americans: Complete Statistical AnalysisIndependent statistical analysis of Personalized Vitamin D Supplementation in European and African Americans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02362269).
- Personalized Warfarin Dosing by Genomics and Computational Intelligence: Complete Statistical AnalysisIndependent statistical analysis of Personalized Warfarin Dosing by Genomics and Computational Intelligence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00872079).
- PERTINENCEIndependent statistical analysis of Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pertussis Infection in Adolescents and Adults With Prolonged Cough: Complete Statistical AnalysisIndependent statistical analysis of Pertussis Infection in Adolescents and Adults With Prolonged Cough: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01597687).
- PERUSEIndependent statistical analysis of A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer: primary…
- PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01205646).